Glaucoma

Ocular Therapeutics has signed non-disclosure agreements with two of the largest pharmaceutical firms in the world. The unnamed companies are interested in a new treatment approach in the largest of the ophthalmic markets.

Alcon has discontinued development of anecortave acetate for the reduction of intraocular pressure (IOP) associated with glaucoma.

A study reported in the July issue of Ophthalmology, the journal of the American Academy of Ophthalmology correlates the incidence of silent cerebral infarcts (SCI) and visual field loss in patients with normal-tension glaucoma.

Long-term SLT experience

Ocular applications of gene therapies are increasing, as is our understanding of the molecular pathogenesis of glaucoma.

The International Glaucoma Association (IGA) is urging people not to cut back on eye tests due to the recession.

Examing endoscopic cyclophotocoagulation as a treatment for ultra-refractory glaucoma patients.

Some of SLT's leading proponents share their short- and long-term findings with us and discuss the future potential of this treatment.

Looking at OCT as a sensitive diagnostic test for glaucomatous progression.

During the recent ARVO congress, Sylentis provided an update on recent advances made by the company in the development a product for ocular pain associated with dry eye syndrome that addresses TRPV1 receptor, a nociceptor able to transmit stimuli.

Kuldev Singh, MD, Professor of ophthalmology, has been appointed chairman of the Glaucoma Research Foundation (GRF).

Results of the evaluation of two-year post-surgical safety and efficacy of canaloplasty to treat open angle glaucoma (OAG) have been published in the Journal of Cataract and Refractive Surgery. Dr Richard A Lewis et al., concluded that the procedure was safe and effective in reducing IOP in adult OAG patients.

Novagali Pharma, the French pharmaceutical ophthalmic company, is to conduct a Phase III clinical trial of Catioprost (Nova21027) its Investigational New Drug Application (IND).

A look at how to introduce canaloplasty into your surgery; experience from two doctors.

New guidelines, designed to improve the management and diagnosis of chronic open angle glaucoma (COAG) and ocular hypertension have received a cautious commendation from the ophthalmic community.

A worldwide licensing agreement for tafluprost, preserved and preservative-free formulations, has been announced between Merck & Co Inc., and Santen Pharmaceutical Co Ltd.

A Swiss startup company, Sensimed, has developed a novel technology for measuring increases in intraocular pressure.

The investigative research group Catalyst for a Cure has made significant discoveries developing a better understanding of the insidious changes caused by glaucoma and is developing strategies to prevent them.

Dr Christoph Kranemann examines the medium-term success and complication rate of mitomycin-assisted bleb needlings.

While researching the long-suspected gene linked to glaucoma, WDR36, Michael Walter, PhD, and team discovered that the gene STL1 is only one of many other genes in which mutations must take place in order for WDR36 to cause glaucoma.

Dr Vikas Shankar has found that in the diabetic population with OAG, the optic nerve damage occurs at a lower intraocular pressure in comparison with the non-diabetic OAG population and asks: does screening hold the key?

Quantitative analysis of colour vision defects provides the possibility of follow-up and may be a useful means for detecting early glaucomatous changes in patients with normal visual fields.

The investigative research group Catalyst for a Cure has made significant discoveries developing a better understanding of the insidious changes caused by glaucoma and is developing strategies to prevent them.

iForum, a surgeon-support website to enable the adoption of canaloplasty into clinicians' practices, has been launched by iScience Interventional.

The eyecare nutritional supplement market is worth $43.4 million and is projected to grow to $87.4 million within five years, according to research by Frost & Sullivan.